Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform

Abroad (travel likely)Recruiting

Conditions

Early Stage Triple-Negative Breast Carcinoma · Metastatic Bladder Urothelial Carcinoma · Metastatic Cervical Carcinoma · Metastatic Clear Cell Renal Cell Carcinoma · Metastatic Colorectal Carcinoma · Metastatic Endometrial Carcinoma · Metastatic Esophageal Carcinoma · Metastatic Liver Carcinoma · Metastatic Lung Non-Small Cell Carcinoma · Metastatic Malignant Skin Neoplasm · Metastatic Malignant Solid Neoplasm · Resectable Lung Non-Small Cell Carcinoma · Early Stage Lung Non-Small Cell Carcinoma · Resectable Malignant Solid Neoplasm · Resectable Triple-Negative Breast Carcinoma · Stage III Renal Cell Cancer AJCC v8 · Stage IV Cervical Cancer AJCC v8 · Stage IV Renal Cell Cancer AJCC v8 · Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8 · Recurrent Cervical Carcinoma · Recurrent Colorectal Carcinoma · Recurrent Endometrial Carcinoma · Recurrent Esophageal Carcinoma · Recurrent Liver Carcinoma · Recurrent Lung Non-Small Cell Carcinoma · Recurrent Malignant Skin Neoplasm · Recurrent Malignant Solid Neoplasm

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Mayo Clinic in Arizona, Phoenix, Arizona, United States
Contact: Study coordinator (Clinical Trials Referral Office) · mayocliniccancerstudies@mayo.edu · 855-776-0015
Contact: Principal Investigator (Parminder Singh, MD)
Mayo Clinic in Florida, Jacksonville, Florida, United States
Contact: Study coordinator (Clinical Trials Referral Office) · mayocliniccancerstudies@mayo.edu · 855-776-0015
Contact: Principal Investigator (Dev Mukhopadhyay, PhD)
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Contact: Study coordinator (Clinical Trials Referral Office) · mayocliniccancerstudies@mayo.edu · 855-776-0015
Contact: Principal Investigator (Matthew Block, MD, PhD)

Study leads

Dev Mukhopadhyay, PhD
Principal Investigator
Mayo Clinic

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

Anatomic Stage II Breast Cancer AJCC v8 · Anatomic Stage IIIA Breast Cancer AJCC v8 · Triple-Negative Breast Carcinoma

Abroad (travel likely)RecruitingPHASE2

Nashville, United States

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

Anatomic Stage II Breast Cancer AJCC v8 · Early Stage Triple-Negative Breast Carcinoma · Anatomic Stage IIIA Breast Cancer AJCC v8

Abroad (travel likely)RecruitingPHASE3

Birmingham, United States · Fairhope, United States

Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial

Anatomic Stage I Breast Cancer AJCC v8 · Anatomic Stage II Breast Cancer AJCC v8 · Early Stage HER2-Positive Breast Carcinoma

Abroad (travel likely)RecruitingPHASE2

Houston, United States

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 · Anatomic Stage II Breast Cancer AJCC v8 · Anatomic Stage IIIA Breast Cancer AJCC v8

Abroad (travel likely)RecruitingPHASE3

Birmingham, United States · Anchorage, United States